Lung Cancer Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Lung Cancer Therapeutics Market: By Treatment Type (Targeted Therapy, Immunotherapy, Chemotherapy), By Disease Type (Non-small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

The global Lung Cancer Therapeutics Market was valued at USD 18,327.8 Million in 2020 and is anticipated to grow at USD 48,736.9 Million till 2027 recording a CAGR of 13.2% during the forecast period 2021-2027. Global lung cancer therapeutics market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in lung cancer therapeutics market. For instance, in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer. Similarly, In September 2014, Asterias Biotherapeutics collaborated with Cancer Research UK for the development of a vaccine for the treatment of non-small cell lung cancer. In April 2017, Takeda Pharmaceutical received an approval from FDA for Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer. In April 2017, AstraZeneca received approval from European Commission for the marketing authorization of Tagrisso used in the treatment of non-small cell lung cancer.

 

Lung Cancer Therapeutics Market

MARKET SUMMARY
-
13.2%
  • Study Period– 2021-2027
  • Base Year– 2020
  • CAGR–13.2%
  • Largest Market– North America
  • Fastest Growing Market– Europe

Lung Cancer Therapeutics Market

  • Cancer is caused by abnormal cell proliferation. Uncontrollable cell growth invades adjacent tissues and spreads to other sections of the body via the lymphatic system. Lung cancer, also known as lung carcinoma, is a disease in which the cells in the lungs grow out of control. Non-small cell lung cancer, small cell lung cancer, and lung carcinoid tumour are the three main kinds of lung cancer.
  • The most frequent type of lung cancer is non-small cell lung cancer. Non-small cell lung cancer accounts for about 85% of all lung cancers. Coughing, chest aches, weight loss, and shortness of breath are all common lung cancer symptoms.
  • Chemotherapy, radiation therapy, vaccinations, and immunotherapies are some of the treatments available for lung cancer. Chemotherapy, targeted therapy, radiotherapy, and geography can all be used to segment the worldwide lung cancer therapies market.
  • The global lung cancer therapies market can be divided into Gemzar, Alimta, Paraplatin, Taxotere, Navelbine, and others based on chemotherapy. Chemotherapy is often based on a medication cocktail. The global lung cancer treatments market can be split into Avastin, Tarceva, Iressa, Gilotrif, and others in terms of targeted therapy.
Market Key Players
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • AstraZeneca
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc.
  • Boehringer Ingelheim GmbH
  • Novartis AG
  • Takeda Pharmaceuticals Co. Ltd.
  • Abbvie, Inc.
  • VisionGate, Inc
  • Asterias Biotherapeutics (Biotime)
Growth

Lung Cancer Therapeutics Market

Lung cancer or lung carcinoma is the disease characterized by the abnormal proliferation of tumour cells in the lung tissues. Lung cancer is classified into 3 types namely lung carcinoid tumour, small cell lung cancer, and non-small cell lung cell cancer. Common symptoms associated with the lung cancer include a cough, weight loss, shortness of breath, and chest pains. Smoking and prolonged use of tobacco are the common risk factors for the lung cancer. Lung cancer can be diagnosed by the biopsy performed by using CT-guidance or bronchoscopy. Lung cancer can be treated by radiotherapy, chemotherapy, and surgery.Increasing pollution owing to rapid industrialization, a rise in the number of tobacco consumption and smoking population, growing government funding for the R&D activities, and rise in demand for targeted therapies are anticipated to fuel the growth of lung cancer therapeutics market. Moreover, innovation of newer radiotherapies, a launch of low priced generic drugs, and rise in prevalence of non-small cell lung cancer are expected to propel the lung cancer therapeutics market over the forecast period. However, stringent regulatory policies, patent expiry of lung cancer therapeutics, poor cancer diagnostics in underdeveloped countries, and adverse effects associated with the treatment might hamper the growth of the market.


North-America Got Significant Share

Lung Cancer Therapeutics Market

Geographically, Lung cancer therapeutics market is segmented into the Europe, Latin America, Asia Pacific, Middle East and Africa, and North America. North America market is growing due to increase in the prevalence of lung cancer majorly in U.S. (according to CDC 2014, about 215,951 people diagnosed with lung cancer and 155,526 people died of the lung cancer). In addition, increase the funding for the R&D activities, and early diagnosis of the disease is expected to propel the market in North America. In Europe region, rise in the prevalence of lung cancer majorly in Hungary, Serbia, U.K and other Europe countries (according to Cancer Research UK, about 46,403 new lung cancer in the UK and 35,895 people died of the disease), rise in the government funding for lung cancer R&D activities, and advanced healthcare infrastructure are boosting the lung cancer therapeutics market. Asia Pacific region is exhibiting significant growth in market owing to rapid industrialization and availability of low-cost generic products in the region.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2020) and forecast (2021 to 2027)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Lung Cancer Therapeutics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content

1. Executive Summary
2. Global Lung Cancer Therapeutics Market Introduction
2.1. Global Lung Cancer Therapeutics Market – Taxonomy
2.2. Global Lung Cancer Therapeutics Market –Definitions
2.2.1. By Treatment Type
2.2.2. By Disease Type
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Lung Cancer Therapeutics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Lung Cancer Therapeutics Market Dynamic Factors – Impact Analysis
3.6. Global Lung Cancer Therapeutics Market – Competition Landscape
3.7. Epidemiology
4. Global Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Lung Cancer Therapeutics Market, By Treatment Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
5.1. Targeted Therapy
5.1.1. Bevacizumab
5.1.1.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.1.3. Market Opportunity Analysis
5.1.2. Dabrafenib/Trametinib
5.1.2.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.2.3. Market Opportunity Analysis
5.1.3. Erlotinib
5.1.3.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3.3. Market Opportunity Analysis
5.1.4. Osimertinib
5.1.4.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.4.3. Market Opportunity Analysis
5.1.5. Others
5.1.5.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.5.3. Market Opportunity Analysis
5.2. Immunotherapy
5.2.1. Durvalumab
5.2.1.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.1.3. Market Opportunity Analysis
5.2.2. Nivolumab
5.2.2.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.2.3. Market Opportunity Analysis
5.2.3. Atezolizumab
5.2.3.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3.3. Market Opportunity Analysis
5.2.4. Pembrolizumab
5.2.4.1. Market Analysis, 2016-2020 and Forecast, 2021-2027 (Revenue, USD Mn)
5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.4.3. Market Opportunity Analysis
5.3. Chemotherapy
5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
6. Global Lung Cancer Therapeutics Market, By Disease Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
6.1. Non-small Cell Lung Cancer (NSCLC)
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Small Cell Lung Cancer (SCLC)
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Lung Cancer Therapeutics Market Forecast, By Distribution Channel, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Lung Cancer Therapeutics Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Region, 2022 – 2028
9. North America Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
9.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Targeted Therapy
9.1.1.1. Bevacizumab
9.1.1.2. Dabrafenib/Trametinib
9.1.1.3. Erlotinib
9.1.1.4. Osimertinib
9.1.1.5. Others
9.1.2. Immunotherapy
9.1.2.1. Durvalumab
9.1.2.2. Nivolumab
9.1.2.3. Atezolizumab
9.1.2.4. Pembrolizumab
9.1.3. Chemotherapy
9.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Non-small Cell Lung Cancer (NSCLC)
9.2.2. Small Cell Lung Cancer (SCLC)
9.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028
9.6. North America Lung Cancer Therapeutics Market Dynamics – Trends
10. Europe Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
10.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Targeted Therapy
10.1.1.1. Bevacizumab
10.1.1.2. Dabrafenib/Trametinib
10.1.1.3. Erlotinib
10.1.1.4. Osimertinib
10.1.1.5. Others
10.1.2. Immunotherapy
10.1.2.1. Durvalumab
10.1.2.2. Nivolumab
10.1.2.3. Atezolizumab
10.1.2.4. Pembrolizumab
10.1.3. Chemotherapy
10.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Non-small Cell Lung Cancer (NSCLC)
10.2.2. Small Cell Lung Cancer (SCLC)
10.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028
10.6. Europe Lung Cancer Therapeutics Market Dynamics – Trends
11. Asia-Pacific Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
11.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Targeted Therapy
11.1.1.1. Bevacizumab
11.1.1.2. Dabrafenib/Trametinib
11.1.1.3. Erlotinib
11.1.1.4. Osimertinib
11.1.1.5. Others
11.1.2. Immunotherapy
11.1.2.1. Durvalumab
11.1.2.2. Nivolumab
11.1.2.3. Atezolizumab
11.1.2.4. Pembrolizumab
11.1.3. Chemotherapy
11.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Non-small Cell Lung Cancer (NSCLC)
11.2.2. Small Cell Lung Cancer (SCLC)
11.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028
11.6. Asia-Pacific Lung Cancer Therapeutics Market Dynamics – Trends
12. Latin America Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
12.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Targeted Therapy
12.1.1.1. Bevacizumab
12.1.1.2. Dabrafenib/Trametinib
12.1.1.3. Erlotinib
12.1.1.4. Osimertinib
12.1.1.5. Others
12.1.2. Immunotherapy
12.1.2.1. Durvalumab
12.1.2.2. Nivolumab
12.1.2.3. Atezolizumab
12.1.2.4. Pembrolizumab
12.1.3. Chemotherapy
12.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Non-small Cell Lung Cancer (NSCLC)
12.2.2. Small Cell Lung Cancer (SCLC)
12.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028
12.6. Latin America Lung Cancer Therapeutics Market Dynamics – Trends
13. Middle East and Africa Lung Cancer Therapeutics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) 
13.1. Treatment Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Targeted Therapy
13.1.1.1. Bevacizumab
13.1.1.2. Dabrafenib/Trametinib
13.1.1.3. Erlotinib
13.1.1.4. Osimertinib
13.1.1.5. Others
13.1.2. Immunotherapy
13.1.2.1. Durvalumab
13.1.2.2. Nivolumab
13.1.2.3. Atezolizumab
13.1.2.4. Pembrolizumab
13.1.3. Chemotherapy
13.2. Disease Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Non-small Cell Lung Cancer (NSCLC)
13.2.2. Small Cell Lung Cancer (SCLC)
13.3. Distribution Channel Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Lung Cancer Therapeutics Market – Opportunity Analysis Index, By Treatment Type, By Disease Type, By Distribution Channel and Country, 2022 – 2028
13.6. MEA Lung Cancer Therapeutics Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche Ltd
14.2.2. Eli Lilly and Company
14.2.3. Celgene Corporation
14.2.4. AstraZeneca plc
14.2.5. Pfizer, Inc.
14.2.6. Sanofi SA
14.2.7. Novartis AG
14.2.8. Bristol Myers Squibb
14.2.9. Merck MSD
14.2.10. Millennium Pharmaceuticals, Inc.
15. Research Methodology
16. Key Assumptions and Acronyms


Report

Company Profile

  • Hoffmann-La Roche Ltd
  •  Eli Lilly and Company
  •  Celgene Corporation
  •  AstraZeneca plc
  •  Pfizer, Inc.
  •  Sanofi SA
  •  Novartis AG
  •  Bristol Myers Squibb
  •  Merck MSD Millennium Pharmaceuticals, Inc.

Description

The global Lung Cancer Therapeutics Market was valued at USD 18,327.8 Million in 2020 and is anticipated to grow at USD 48,736.9 Million till 2027 recording a CAGR of 13.2% during the forecast period 2021-2027. Global lung cancer therapeutics market is growing at a significant CAGR over the forecast timeframe owing to increase in the R&D activities clinical trials for the innovation of new drugs and vaccines for the treatment of lung cancer. Increase in the prevalence of lung cancer (according to world cancer research fund international 2012, lung cancer was the most common cancer which contributes 13% share of the new cancer cases diagnosed) also propelling the market. Acquisitions & mergers, collaborations are the key strategies adopted by the players to gain revenue growth in lung cancer therapeutics market. For instance, in November 2015, Eli Lilly and Co. and Merck & Co., Inc. collaborated to evaluate the efficacy and safety of a combination of the Alimta and Keytruda under phase III trials for the treatment of non-small cell lung cancer. Moreover, in January 2016, VisionGate acquired a patent from University of Colorado for Iloprost used in the treatment of lung cancer. Similarly, In September 2014, Asterias Biotherapeutics collaborated with Cancer Research UK for the development of a vaccine for the treatment of non-small cell lung cancer. In April 2017, Takeda Pharmaceutical received an approval from FDA for Alunbrig (brigatinib) used in the treatment of ALK+ non-small cell lung cancer. In April 2017, AstraZeneca received approval from European Commission for the marketing authorization of Tagrisso used in the treatment of non-small cell lung cancer.

 

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX